Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All drugs

Anlotinib + Epirubicin (neoadjuvant)

Stage Phase 2

Sponsor Eye and ENT Hospital of Fudan University

Modality small molecule

Class multi-kinase TKI with chemotherapy

Target VEGFR1 to 3 (KDR, FLT1, FLT4) (TEC-0075)

Sources

registry, as of 2026-11-07

https://clinicaltrials.gov/api/v2/studies?query.cond=adenoid%20cystic%20carcinoma

ClinicalTrials.gov API v2, 2026-11-07: 40 active ACC-condition records; records updated since 10.20.2026 opened (raw/ctgov_new/): VMD-928 (TrkA) NCT03556228, Phase 1/2, VM Oncology, recruiting, n 242 est., PCD 2027-12, conditions list ACC; SX-682 plus docetaxel NCT07667400, Phase 1/2, NCI, includes salivary gland carcinoma, n 120 est., PCD 2036-10-01; neoadjuvant anlotinib plus epirubicin NCT07616141, Phase 2, Fudan Eye and ENT Hospital, T4 sinonasal ACC, n 76 est., PCD 2028-06-01; P-Sam NCT07162480 recruiting, PCD 2029-12-31. No ACC Phase 3 registered.

Brief source A35

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT07616141

Neoadjuvant Anlotinib Combined With Epirubicin for T4 Stage Sinonasal Adenoid Cystic Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

NAET4-SNACC

Registry NCT07616141

Phase Phase 2

Status Recruiting

Enrollment 76

Start 2026-06-01

Primary completion 2028-06-01

Study completion 2031-06-01

Catalyst Primary completion. 06.01.2028. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.